Year All2024202320222021 December 31, 2021 Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform June 30, 2021 ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset
December 31, 2021 Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
June 30, 2021 ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset